Streamlining VUS Classification in Clinical Genomics
November 14, 2025
-
4 min
7 Key Takeaways
-
1
One-third of symptomatic genetic tests yield VUS.
-
2
VUS complicate clinical decisions.
-
3
New classification standards aim to reduce VUS.
-
4
Improved data sharing is crucial for reclassification.
-
5
Advances in computational genomics enhance variant interpretation.
-
6
SVCv4 allows for easier classification to 'likely benign'.
-
7
Functional assessment scales increase laboratory testing capacity.
Experts are focusing on reducing the prevalence of Variants of Uncertain Significance (VUS) in genetic testing, recognizing it as a significant challenge for precision genomic medicine. At the recent AMP annual meeting, Dr. Heidi L. Rehm discussed strategies to manage VUS, highlighting that about one-third of symptomatic tests yield inconclusive results which can complicate treatment decisions for patients and clinicians. New classification standards aim to streamline the interpretation of these variants, encouraging better data sharing and the use of advanced computational tools.
Listen Tab content
